Urinary tract infections in the intradetrusor onabotulinumtoxinA population
Published: 17 April 2023
Abstract Views: 822
PDF: 200
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The aim of our study was to determine the incidence of Urinary Tract Infections (UTI) following intradetrusor onabotulinumtoxinA injections within our trust. This was a retrospective study of all patients who underwent intradetrusor onabotulinumtoxinA injections at our trust from August 2005 to 2015. Information was taken from our botulinum database, clinic letters and microbiology results. The primary outcome criterion was a positive urine culture together with symptoms suggestive of infection within 6 months post-procedure. A total of 290 intradetrusor onabotulinumtoxinA procedures were performed on 86 patients. The rate of UTI within 6 months following a procedure was 33%. There was a high resistance rate to our standard antibiotic prophylaxis, which was changed together with the addition of pre-procedure urine cultures and an on the day urine dipstick test. A re-audit was performed between January and June 2016 of 41 procedures and showed a reduction in UTI incidence to 20%. The rate of UTI post procedure within our trust was 33%. Following the implementation of multiple management protocol changes, a re-audit showed a reduction of UTI incidence to 20%.
Altmetrics
Downloads
Download data is not yet available.
Citations
Abrams P, Artibani W, Cardozo L, et al. International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28:287. DOI: https://doi.org/10.1002/nau.20737
National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE Guideline No. 123, 2019. Accessed 27/01/23. Available from: www.nice.org.uk/guidance/ng123
Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-19. DOI: https://doi.org/10.1016/j.eururo.2008.09.009
Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9. DOI: https://doi.org/10.1016/j.juro.2012.01.125
Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin Botox®, intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275-287. DOI: https://doi.org/10.1016/j.eururo.2007.10.013
Mouttalib S, Khan S, Castel-Lacanal E, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 2010;106:1677-80. DOI: https://doi.org/10.1111/j.1464-410X.2010.09435.x
Zhou X, Yan HL, Cui YS, et al. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) 2015;128:963-8. DOI: https://doi.org/10.4103/0366-6999.154318
Sun Y, Luo D, Tang C, et al. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol 2015;47:1779-88. DOI: https://doi.org/10.1007/s11255-015-1125-7
Bootsma AM, Laguna Pes MP, Geerlings SE, et al. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 2008;54:1270-86. DOI: https://doi.org/10.1016/j.eururo.2008.03.033
European Association of Urology (EAU). EAU Guidelines on urological infections. 3.15 Peri-procedural antibiotic prophylaxis. 2022; 47-52. Accessed 27/01/23. Available from: http://uroweb.org/guideline/urological-infections/
Bickhaus JA, Vaughan M, Truong T, et al. A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. Int Urogynecol J 2020;31:1907-1912. DOI: https://doi.org/10.1007/s00192-020-04230-7
Public Health England, 2019. UK Standards for microbiology investigations. Accessed 28/01/2023] Available from: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories
Sartori AM, Padilla-Fernández B, 't Hoen L, et al. Definitions of urinary tract infection used in interventional studies involving neurourological patients- a systematic review. European Urology Focus 2022;8:1386-1398. DOI: https://doi.org/10.1016/j.euf.2021.07.012
Arruda RM, Takano CC, Girão MJBC, et al. Treatment of non-neurogenic overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis of prospective, randomized, placebo-controlled clinical trials. Rev Bras Ginecol Obstet (Engl) 2018;40:225-231. DOI: https://doi.org/10.1055/s-0038-1642631
How to Cite
Urinary tract infections in the intradetrusor onabotulinumtoxinA population. (2023). Urogynaecologia, 35(1). https://doi.org/10.4081/uij.2023.304
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- F. Mantovani, A. Del Nero, S. Confalonieri, E. Pisani, COLLAGEN FOR U.I. MINIMAL DOSE INJECTIONS IN SCHEDULED STEPS TO IMPROVE CLINICAL RESULTS , Urogynaecologia: Vol. 16 No. 1 (2002)
- Shoeb Alahmad, Rawaa AlKayali, Lubana Alkhoder, Gihad Allugamie, The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study , Urogynaecologia: Vol. 36 No. 1 (2024)
- V. LEANZA, M. BOLOGNA, N. GASBARRO, TENSION-FREE TECHNIQUES IN UROGYNAECOLOGICAL SURGERY , Urogynaecologia: Vol. 19 No. 2-3 (2005)
- Bambang Sasongko Noegroho, Akhmad Mustafa, Predictive factor for successful retrograde ureteral stent insertion in obstructive uropathy due to advanced cervical cancer , Urogynaecologia: Vol. 31 No. 1 (2019)
- P. Liguori, R. Ripoli, REPAIR OF POSTERIOR VAGINAL WALL DEFECTS WITH PELVICOL™ IMPLANT ANCHORED TO ILIOCOCCYGEUS , Urogynaecologia: Vol. 20 No. 1 (2006)
- F. BERNASCONI, G. PISANI, S. ARIENTI, B. VERONESE, S. PITTALIS, M. CONTI, M. TASSI, S. GELOSA, A. BIELLA, C. CERRI, Uro-rehabilitation and effort urinary incontinence: medium-term results and analysis of the failure risk factors. , Urogynaecologia: Vol. 15 No. 2 (2001)
- M. Tamburello, V. Farruggia, S.M. Rubino, TWO CASES OF BLADDER PROLENE® TAPE EXPOSURE AFTER TVT PROCEDURE , Urogynaecologia: Vol. 16 No. 1 (2002)
- R. Baccichet, C. Braghin, A. Azzena, MINIMALLY-INVASIVE TRANSOBTURATOR CORRECTION OF CYSTOCELE , Urogynaecologia: Vol. 20 No. 3 (2006)
- Theo Malthouse, Ian Rudd, Chris Down, James Moore, Autologous mid-urethral fascial sling for stress urinary incontinence: Long term outcomes , Urogynaecologia: Vol. 33 No. 1 (2021)
- Evert L. Koldewijn, Dennis J.A.J. Oerlemans, Alexander Beulens, Michel J.A.M. de Wildt, Vera Vandoninck, Stefan De Wachter, Treatment of mild to moderate stress urinary incontinence with a novel polycaprolactonebased bioresorbable urethral bulking agent , Urogynaecologia: Vol. 34 No. 1 (2022)
You may also start an advanced similarity search for this article.